# OnCo record telisotuzumab-vedotin (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/telisotuzumab-vedotin/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "telisotuzumab-vedotin" ;
  schema:name "Telisotuzumab vedotin"@en ;
  schema:description "Telisotuzumab vedotin (Emrelis) is the first c-MET-directed ADC, approved in 2025 for lung cancer with high c-MET protein."@en ;
  schema:url <https://onco.cc/drugs/telisotuzumab-vedotin/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Telisotuzumab%20vedotin> ;
  onco:status "approved" ;
  onco:modality "ADC" ;
  schema:alternateName "Emrelis" ;
  onco:approval "US 2025: c-MET-high non-squamous NSCLC, previously treated (accelerated)" ;
  onco:acceleratedApproval "US 2025-05-14: Treatment of adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [≥50% of tumor cells with strong (3+) staining], as determined by an FDA-approved test, who have received a prior systemic therapy." ;
  onco:related <https://onco.cc/biomarkers/met-overexpression/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/met-altered-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/met/> ;
  onco:companies <https://onco.cc/companies/abbvie/> ;
  onco:terms <https://onco.cc/terms/mc-vc-pabc/> ;
  onco:trials <https://onco.cc/trials/luminosity/>, <https://onco.cc/trials/nct06568939/> .